Stanford Researchers Use AI to Identify Natural GLP-1 Alternative
AI-Driven Drug Discovery Targets Natural GLP-1 Pathway
Researchers at Stanford University have applied artificial intelligence to identify a natural compound that could provide the weight-loss and metabolic benefits of GLP-1 receptor agonists like Ozempic and Wegovy, but without the common adverse effects that often lead patients to discontinue treatment.
The team used machine learning models to screen vast databases of natural compounds, looking for molecules that could activate the GLP-1 pathway—which regulates blood sugar and appetite—without triggering the nausea and gastrointestinal distress that frequently accompany current injectable medications.
Potential Advantages of a Natural Alternative
If successfully developed, such a compound could address one of the major limitations of existing GLP-1 therapies: the side-effect profile that causes roughly 10-15% of patients to stop taking the drugs within the first year. Natural compounds may also offer benefits such as lower manufacturing costs and broader accessibility.
The research represents an emerging trend in pharmaceutical development where AI accelerates the identification of promising candidates that would take considerably longer to discover through traditional laboratory screening methods alone.